
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5390457/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infection. PLoS Pathogens, 2022, 18, e1010507.	2.1	4
2	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. PLoS Pathogens, 2022, 18, e1010574.	2.1	6
3	The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. PLoS Pathogens, 2021, 17, e1010162.	2.1	11
4	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nature Medicine, 2020, 26, 1776-1787.	15.2	63
5	Tetherin downmodulation by SIVmac Nef lost with the H196Q escape variant is restored by an upstream variant. PLoS ONE, 2020, 15, e0225420.	1.1	3
6	Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8 ⁺ T cells. Science Translational Medicine, 2019, 11, .	5.8	81
7	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 515-521.	2.0	24
8	Mechanisms of reactivation of latent tuberculosis infection due to SIV coinfection. Journal of Clinical Investigation, 2019, 129, 5254-5260.	3.9	52
9	Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. Virology, 2018, 514, 106-117.	1.1	29
10	Polymorphisms in Rhesus Macaque Tetherin Are Associated with Differences in Acute Viremia in Simian Immunodeficiency Virus Δ nef -Infected Animals. Journal of Virology, 2018, 92, .	1.5	7
11	The SIV Envelope Glycoprotein, Viral Tropism, and Pathogenesis: Novel Insights from Nonhuman Primate Models of AIDS. Current HIV Research, 2018, 16, 29-40.	0.2	12
12	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood, 2017, 129, 906-916.	0.6	56
13	CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo. Retrovirology, 2016, 13, 22.	0.9	13
14	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	13.9	391
15	Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. Journal of Virology, 2016, 90, 4966-4980.	1.5	9
16	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathogens, 2016, 12, e1005983.	2.1	43
17	Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. Journal of Virology, 2015, 89, 10156-10175.	1.5	19
18	Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy–treated macaques. Nature Methods, 2015, 12, 427-432.	9.0	153

#	Article	IF	CITATIONS
19	Mutations in HIV-1 Envelope That Enhance Entry with the Macaque CD4 Receptor Alter Antibody Recognition by Disrupting Quaternary Interactions within the Trimer. Journal of Virology, 2015, 89, 894-907.	1.5	46
20	Quantification of Entry Phenotypes of Macrophage-Tropic HIV-1 across a Wide Range of CD4 Densities. Journal of Virology, 2014, 88, 1858-1869.	1.5	92
21	Generating an Anti-HIV Vaccine Using Nucleoside-modified mRNA Encoding Envelope. AIDS Research and Human Retroviruses, 2014, 30, A249-A249.	0.5	1
22	Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques. Virology, 2014, 458-459, 53-68.	1.1	15
23	A Single Amino Acid Mutation in the Envelope Cytoplasmic Tail Restores the Ability of an Attenuated Simian Immunodeficiency Virus Mutant To Deplete Mucosal CD4 ⁺ T Cells. Journal of Virology, 2013, 87, 13048-13052.	1.5	9
24	Loss of a Tyrosine-Dependent Trafficking Motif in the Simian Immunodeficiency Virus Envelope Cytoplasmic Tail Spares Mucosal CD4 Cells but Does Not Prevent Disease Progression. Journal of Virology, 2013, 87, 1528-1543.	1.5	32
25	CD4 ⁺ T Cells Support Production of Simian Immunodeficiency Virus Env Antibodies That Enforce CD4-Dependent Entry and Shape Tropism <i>In Vivo</i> . Journal of Virology, 2013, 87, 9719-9732.	1.5	12
26	Novel Cell and Gene Therapies for HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007179-a007179.	2.9	54
27	Three-Dimensional Structures of Soluble CD4-Bound States of Trimeric Simian Immunodeficiency Virus Envelope Glycoproteins Determined by Using Cryo-Electron Tomography. Journal of Virology, 2011, 85, 12114-12123.	1.5	46
28	Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. PLoS Pathogens, 2011, 7, e1002020.	2.1	130
29	Distinct Molecular Pathways to X4 Tropism for a V3-Truncated Human Immunodeficiency Virus Type 1 Lead to Differential Coreceptor Interactions and Sensitivity to a CXCR4 Antagonist. Journal of Virology, 2010, 84, 8777-8789.	1.5	9
30	Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure. PLoS Pathogens, 2010, 6, e1001249.	2.1	161
31	Toward an Antibody-Based HIV-1 Vaccine. Annual Review of Medicine, 2010, 61, 135-152.	5.0	110
32	Derivation and Characterization of a Simian Immunodeficiency Virus SIVmac239 Variant with Tropism for CXCR4. Journal of Virology, 2009, 83, 9911-9922.	1.5	21
33	Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. Journal of Virology, 2009, 83, 1045-1059.	1.5	238
34	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. Journal of Virology, 2009, 83, 1240-1259.	1.5	67
35	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. Journal of Virology, 2009, 83, 5077-5086.	1.5	43
36	HIV Vaccine Research: The Way Forward. Science, 2008, 321, 530-532.	6.0	229

3

#	Article	IF	CITATIONS
37	V3 Loop Truncations in HIV-1 Envelope Impart Resistance to Coreceptor Inhibitors and Enhanced Sensitivity to Neutralizing Antibodies. PLoS Pathogens, 2007, 3, e117.	2.1	68
38	Replication-Competent Variants of Human Immunodeficiency Virus Type 2 Lacking the V3 Loop Exhibit Resistance to Chemokine Receptor Antagonists. Journal of Virology, 2007, 81, 9956-9966.	1.5	32
39	Tuberculosis and HIV Coinfection: Genesis of the Supplement and Sponsors' Contribution. Journal of Infectious Diseases, 2007, 196, S4-S4.	1.9	0
40	A Conserved Dileucine Motif Mediates Clathrin and AP-2–dependent Endocytosis of the HIV-1 Envelope Protein. Molecular Biology of the Cell, 2007, 18, 414-425.	0.9	120
41	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. Journal of Experimental Medicine, 2005, 201, 1407-1419.	4.2	296
42	Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein. Journal of Virology, 2001, 75, 5230-5239.	1.5	135
43	CD4-Independent Use of Rhesus CCR5 by Human Immunodeficiency Virus Type 2 Implicates an Electrostatic Interaction between the CCR5 N Terminus and the gp120 C4 Domain. Journal of Virology, 2001, 75, 10766-10778.	1.5	22
44	In Vivo Attenuation of Simian Immunodeficiency Virus by Disruption of a Tyrosine-Dependent Sorting Signal in the Envelope Glycoprotein Cytoplasmic Tail. Journal of Virology, 2001, 75, 278-291.	1.5	78
45	The Simian Immunodeficiency Virus Envelope Glycoprotein Contains Multiple Signals that Regulate its Cell Surface Expression and Endocytosis. Traffic, 2000, 1, 661-674.	1.3	64
46	Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein. Journal of Virology, 2000, 74, 7922-7935.	1.5	62
47	Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity. Journal of Virology, 1999, 73, 10310-10319.	1.5	111
48	Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1999, 73, 7489-7496.	1.5	77
49	CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. Journal of Reproductive Immunology, 1998, 41, 197-211.	0.8	55
50	Construction of single-chain antibodies that bind an overlapping epitope of HIV-1 Nef. FEBS Letters, 1998, 441, 307-312.	1.3	17
51	Human Immunodeficiency Virus-1 Entry Into Purified Blood Dendritic Cells Through CC and CXC Chemokine Coreceptors. Blood, 1997, 90, 1379-1386.	0.6	119
52	Common mechanism of infection by lentiviruses. Nature, 1997, 385, 587-587.	13.7	97
53	CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Current Biology, 1997, 7, 112-121.	1.8	486
54	Roles for endocytosis in lentiviral replication. Trends in Cell Biology, 1997, 7, 1-4.	3.6	23

#	Article	IF	CITATIONS
55	Human Immunodeficiency Virus-1 Entry Into Purified Blood Dendritic Cells Through CC and CXC Chemokine Coreceptors. Blood, 1997, 90, 1379-1386.	0.6	8
56	CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4. Cell, 1996, 87, 745-756.	13.5	729
57	Signaling through G Proteins and G Protein-coupled Receptors during Platelet Activation. Thrombosis and Haemostasis, 1993, 70, 217-223.	1.8	104